Kinopharma, Inc.

Kyoto University

Tokyo Medical and Dental University

Hiroshi Onogi

Takamitsu Hosoya

Masatoshi Hagiwara

Isao Kii

Yuto Sumida

Masaaki Suzuki

Hiroko Koyama

Toshiyuki Hiramatsu

The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition. One or more embodiments disclose a compound expressed by the following general formula (I) or (II) or a pharmaceutically acceptable salt of the compound: 

Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor

Viruses, and particularly RNA viruses, have high mutation rates. Hence, antiviral agents that have been developed to date targeting protease or reverse transcriptase of viruses have quickly lost their effectiveness and resistant viruses have emerged. Also, in recent years, viral diseases caused by various new viruses such as SARS, avian influenza, and the hepatitis C have become social menaces. Therefore, the development of a novel antiviral agent that can cope with a virus resistant to an existing drug or a new virus and has a wide range of applications has been demanded. The present invention provides a novel anti-RNA viral agent and a method for use thereof. The present invention further provides an anti-RNA viral agent that is also effective against a new virus or a drug-resistant virus, and a method for use thereof.

Aniline derivative having anti-RNA viral activity

Growing community of inventors

Tokyo, Japan

Hiroshi Onogi